Technical Analysis for MYL - Mylan Inc.

Grade Last Price % Change Price Change
grade D 31.84 1.02% 0.32
MYL closed up 1.02 percent on Friday, February 15, 2019, on 63 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Feb 26

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical MYL trend table...

Date Alert Name Type % Chg
Feb 15 Narrow Range Bar Range Contraction 0.00%
Feb 15 NR7 Range Contraction 0.00%
Feb 15 Overbought Stochastic Strength 0.00%
Feb 14 Stochastic Sell Signal Bearish 1.02%
Feb 14 Inside Day Range Contraction 1.02%
Feb 14 Overbought Stochastic Strength 1.02%
Feb 13 Slingshot Bullish Bullish Swing Setup 1.89%
Feb 13 Outside Day Range Expansion 1.89%
Feb 13 Overbought Stochastic Strength 1.89%
Feb 12 Gapped Up Strength 0.32%

Older signals for MYL ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. The company also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form (FDF) products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.
Health Life Sciences Pharmaceutical Industry Pharmaceuticals Pharmaceutical Industry In China Pharmaceuticals Policy Active Pharmaceutical Ingredients Hiv/Aids Generic Drug Healthcare Institutions Generic Pharmaceutical Products Disorder Pharmaceutical Wholesalers Drug Manufacturers Injectable Products
Is MYL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 44.18
52 Week Low 26.035
Average Volume 4,649,359
200-Day Moving Average 34.9237
50-Day Moving Average 29.4526
20-Day Moving Average 30.1875
10-Day Moving Average 31.109
Average True Range 0.861
ADX 18.44
+DI 27.586
-DI 19.3666
Chandelier Exit (Long, 3 ATRs ) 29.467
Chandelier Exit (Short, 3 ATRs ) 30.343
Upper Bollinger Band 32.5499
Lower Bollinger Band 27.8251
Percent B (%b) 0.85
BandWidth 15.651511
MACD Line 0.5783
MACD Signal Line 0.3955
MACD Histogram 0.1828
Fundamentals Value
Market Cap 17.08 Billion
Num Shares 536 Million
EPS 1.24
Price-to-Earnings (P/E) Ratio 25.68
Price-to-Sales 1.72
Price-to-Book 1.61
PEG Ratio 1.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.32
Resistance 3 (R3) 32.29 32.10 32.24
Resistance 2 (R2) 32.10 31.98 32.12 32.21
Resistance 1 (R1) 31.97 31.90 31.88 32.00 32.19
Pivot Point 31.78 31.78 31.73 31.80 31.78
Support 1 (S1) 31.65 31.66 31.56 31.68 31.49
Support 2 (S2) 31.46 31.58 31.48 31.47
Support 3 (S3) 31.33 31.46 31.44
Support 4 (S4) 31.36